2019
Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
Department of Internal Medicine Y, Sutaria R, Patel P, Department of Rheumatology Y, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. European Journal Of Rheumatology 2019, 6: 153-154. PMID: 30986169, PMCID: PMC6668642, DOI: 10.5152/eurjrheum.2019.18159.Peer-Reviewed Original ResearchMetastatic melanomaCheckpoint inhibitorsMyasthenia gravisAutoimmune myositisCombination of ipilimumabCytotoxic T lymphocytesCombination therapyT lymphocytesImmune responseAdverse effectsMelanomaNumerous immuneIpilimumabNivolumabNovel optionGravisMyositisDeactivation signalsInhibitorsMalignancyTherapyTumors
2015
IL-17 Inhibition in Axial Spondyloarthritis
Danve A, Deodhar A. IL-17 Inhibition in Axial Spondyloarthritis. Current Treatment Options In Rheumatology 2015, 1: 221-230. DOI: 10.1007/s40674-015-0020-9.Peer-Reviewed Original ResearchIL-23/ILIL-17IL-23Monoclonal antibodiesExtra-articular manifestationsTNF-α blockadeIL-17 inhibitionIL-23 receptorQuality of lifeSignificant beneficial effectDisease activityProspective trialRadiographic progressionInhibitor medicationIL-12MRI scoresPhysical functionAxial spondyloarthritisClinical studiesP40 subunitAnimal modelsBeneficial effectsWestern populationsNovel optionSpondyloarthritis